Aditxt Inc
Company Profile
Business description
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
Contact
2569 Wyandotte Street
Suite 101
Mountain ViewCA94043
USAT: +1 650 870-1200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
26
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
stocks
Chart of the Week: How private companies are reshaping public markets
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,085.80 | 8.90 | 0.10% |
| CAC 40 | 7,995.98 | 78.25 | -0.97% |
| DAX 40 | 23,910.60 | 139.14 | -0.58% |
| Dow JONES (US) | 47,231.49 | 79.51 | -0.17% |
| FTSE 100 | 9,758.21 | 18.87 | -0.19% |
| HKSE | 26,485.90 | 550.49 | 2.12% |
| NASDAQ | 23,403.01 | 96.78 | -0.41% |
| Nikkei 225 | 50,251.12 | 632.56 | -1.24% |
| NZX 50 Index | 13,639.19 | 62.38 | 0.46% |
| S&P 500 | 6,780.50 | 15.79 | -0.23% |
| S&P/ASX 200 | 8,821.50 | 11.00 | 0.12% |
| SSE Composite Index | 4,007.76 | 38.51 | 0.97% |